Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs.

Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs. Abstract Text:

Nonsteroidal anti-inflammatory drugs (NSAIDs) represent the most commonly used medications for the treatment of pain and inflammation, but numerous well-described adverse drug reactions (ADRs) limit their use. These drugs act via the inhibition of cyclooxygenase (COX) enzyme of which at least two isoforms were described: COX-1 which plays important roles in homeostatic processes such as thrombogenesis and homeostasis of the gastrointestinal tract and kidneys and COX-2 expressed in pathological conditions such as inflammation or cancer proliferation. Selective COX-2 inhibitors or "coxibs" were initially developed as a therapeutic strategy to avoid not only the gastrointestinal but also the renal and cardiovascular side effects of non specific NSAIDs. However, this class of drug did not fulfill all their promises. Indeed, numerous unexpected side effects have limited their use and some of them have been withdrawn or suspended from the market for different safety reasons including cardiovascular, hepatic and skin adverse reactions. For instance, cardiovascular warnings have been applied to the whole class of coxibs and more recently for all classical NSAIDs as well. However, differences in the chemical structures should be taken into consideration in order to discriminate between coxibs and the development of some ADRs of which renal events and hypertension. The aim of this paper is to focus on the differences in chemical structures of all marketed COX-2 inhibitors and their unexpected effects on carbonic anhydrase in order to provide non-COX-2 mechanistic insights into some of the differences observed between coxibs.

Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Current pharmaceutical design

VOLUME: 14

Page Numbers: 679-84

Journal Abbreviation: Curr. Pharm. Des.

ISSN: 1873-4286

DAY: 13

MONTH: 03

YEAR: 2008

Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9602487

Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs.

AFFILIATION: University of Namur, Drug Design and Discovery Center, Department of Pharmacy, 61 rue de Bruxelles, 5000 Namur, Belgium. jean-michel.dogne@dundp.ac.be.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Pharm Des

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs Related Publications

• Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs.
• Carbonic anhydrase IX: A new druggable target for the design of antitumor agents.
• Carbonic anhydrase activation and the drug design.
• Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines.
• Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I and II, and extracellular isoforms IV, IX, and XII with sulfamides incorporating sugar moieties.
• Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II and IX with some 1,3,4-oxadiazole- and 1,2,4-triazole-thiols.
• Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
• Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.
• Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
• Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies.
• Carbonic anhydrase inhibitors: Cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.
• Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.
• Carbonic anhydrase inhibitors: inhibition of human cytosolic isozymes I and II and tumor-associated isozymes IX and XII with S-substituted 4-chloro-2-mercapto-5-methyl-benzenesulfonamides.
• Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV).
• Carbonic anhydrase inhibitors: the inhibition profiles of the human mitochondrial isoforms VA and VB with anions are very different.
• Carbonic anhydrase inhibitors: the very weak inhibitors dithiothreitol, beta-mercaptoethanol, tris(carboxyethyl)phosphine and threitol interfere with the binding of sulfonamides to isozymes II and IX.
• Carbonic anhydrases - an overview.
• Carbonic anhydrases as drug targets.
• Carbonic anhydrases: novel therapeutic applications for inhibitors and activators.
• Comparative QSAR study on para-substituted aromatic sulphonamides as CAII inhibitors: information versus topological (distance-based and connectivity) indices.
• Design of zinc binding functions for carbonic anhydrase inhibitors.
• Design, synthesis, and docking studies of new 1,3,4-thiadiazole-2-thione derivatives with carbonic anhydrase inhibitory activity.
• Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides.
• Fluorescence- and spin-labeled carbonic anhydrase inhibitors.
• Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors.
• Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and XIII with 4-nitrophenyl esters as substrates.
• Metal-Based Antibacterial and Antifungal Agents: Synthesis, Characterization, and In Vitro Biological Evaluation of Co(II), Cu(II), Ni(II), and Zn(II) Complexes With Amino Acid-Derived Compounds.
• QSAR studies on the activation of the human carbonic anhydrase cytosolic isoforms I and II and secretory isozyme VI with amino acids and amines.
• The alpha and beta Classes Carbonic Anhydrases from Helicobacter pylori as Novel Drug Targets.
• The alpha-carbonic anhydrase from the malaria parasite and its inhibition.